C2300 Archer TP-Link AC2300 (Refurbished) Router Gigabit MU-MIMO Wireless Wireless Routers

  1. Home
  2. C2300 Archer TP-Link AC2300 (Refurbished) Router Gigabit MU-MIMO Wireless
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
TP-Link Archer C2300 AC2300 Wireless MU-MIMO Gigabit Router (Refurbished)
Condition: Manufacturer refurbished: An item that has been professionally restored to working order by a manufacturer or Network Connectivity: Wired-Ethernet (RJ-45), Wireless-Wi-Fi 802.11a, Wireless-Wi-Fi 802.11ac, Wireless-Wi-Fi 802.11b, Wireless-Wi-Fi 802.11g, Wireless-Wi-Fi 802.11n
Number of LAN Ports: 4 Model:

Archer C2300



Country/Region of Manufacture: China
Max. Wireless Data Rate: 2300 Mbps MPN:

Does Not Apply

Features: MU-MIMO, TL-Link HomeCare, Airtime Fairness, Beamforming, Dual Band, VPN Capabilities Max. LAN Data Rate: 1000 Mbps


published on tue nov 09 2021

C2300 Archer TP-Link AC2300 (Refurbished) Router Gigabit MU-MIMO Wireless Wireless Routers

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

C2300 Archer TP-Link AC2300 (Refurbished) Router Gigabit MU-MIMO Wireless Wireless Routers

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.